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Our lab has previously showed that carnosol, a naturally occurring polyphenol, 
exhibits anti-cancer activity by promoting cell cycle arrest at G2 phase, induces 
reactive oxygen species (ROS) dependent apoptosis and beclin-1 independent 
autophagy in triple negative breast cancer (TNBC) cell line (MDA-MB-231). Here, 
we extended our study by investigating the potential effect of carnosol on migration, 
invasion and tumor growth of these cells. Our findings demonstrated that carnosol, at 
non-cytotoxic concentrations, exerted a potent anti-metastatic and anti-tumor growth 
activity against the highly invasive TNBC cell line, MBA-MB-231. Carnosol 
inhibited the migration and invasion of MDA-MB-231 cells. Moreover, carnosol 
suppressed the expression and activity of MMP-2 and MMP-9. Remarkably, our 
investigation revealed that TNF-α and STAT3 proteins that are involved in invasion 
and metastasis signaling were inhibited in MDA-MB-231 cells in response to 
carnosol. Furthermore, we demonstrated that carnosol significantly inhibited tumor 
growth and metastasis in vivo. In conclusion, our findings identify carnosol as a 
promising chemopreventive and chemotherapeutic candidate that modulate breast 
cancer growth and metastasis. Hence, carnosol deserves further study and 
exploration to identify its downstream mechanism(s) of action.  
 
 








Title and Abstract (in Arabic) 
 
 على سرطان الثديتأثیر مضادات االنتشار و مضادات النمو في الكارنوسول 
  صالملخ
وھو مركب طبیعي ) carnosol(توصل مختبرنا مؤخراً أن مركب الكارنوسول                
یحتوي على مضادات للسرطنة من خالل إیقاف دورة الخلیة على مرحلة معینة وانتحار الخلیة 
 ١من خالل تحفیز صنع المشتقات التفاعلیة لألكسجین واالتھام الذاتي اعتماداً على بیكلین
)beclin-1 (في سرطان الثدي ثالثي السلبیة triple-negative breast cancer )MDA-
MB-231( حالیاً، في ھذه األطروحة مددنا دراستنا للتحقُق من مضادات السرطنة في .
السرطانیة. وتوصلنا مؤخراً بأن الكارنوسول على الثدي الكارنوسول على ھجرة واجتیاح ونمو 
تراكیز غیر سامة قادر على منع انتشار ونمو ھذه الخالیا العدوانیة وھي خالیا سرطان الثدي 
. في الواقع، فقد قررنا أن الكرنوسول قادر triple-negative breast cancer ةثالثي السلبی
. وإضافة إلى ذلك وجدنا أن )MDA-MB-231( على منع ھجرة وغزو خالیا سرطان الثدي
. ولفت )MMP-2 and MM-9( الكارنوسول قادر على تثبیط تعبیر ونشاط ھذه البروتینات
ً قدرة تثبیط الكارنوسول على منع ھذه البروتینات  التي  )TNF-α and STAT3(نظرنا أیضا
تتضمن في مسار ھجرة واجتیاح ھذه الخالیا. وعالوة على ذلك، أثبتنا أھمیة الكارنوسول على 
یھا . وفي الختام، النتائج التي توصلنا إل)in vivo( منع نمو وانتشار السرطان على الكائن الحي
 chemopreventive and(اظھرت الكارنوسول على انھ معالج كیمیائي وواقي 
chemotherapeutic(   .واعد بحیث انھ قادر على التالعب بھجرة ونمو سرطان الثدي
 وبالتالي ، كارنوسول یستحق المزید من الدراسة واالستكشاف لتحدید آلیة العمل.
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Chapter 1: Introduction 
	
1.1 Cancer 
1.1.1 Brief history of cancer  
Cancer has been known to mankind since ancient times. Cancer initiates 
when cells in a certain part of the body start to grow out of control. The study of 
cancer is termed oncology. One of the first evidence of the existence of cancer was 
discovered in fossilized bone tumors in human mummies in ancient Egypt. As it was 
referenced in ancient manuscripts, bony skull damage was seen in the head and neck 
also. Although the term cancer was not used, the oldest explanation of cancer was 
found in a book called “Edwin Smith Papyrus” which dates back to about 3000 
BC[1]. The word cancer was coined by the Greek physician, Hippocrates who is 
considered as the father of medicine (460-370 BC). Hippocrates used the Greek 
terms, carcinos and carcinoma to describe tumors. In fact, this term is used to 
describe a crab movement , which he thought behaved like a tumor[2], [3].  
1.1.2 Cancer epidemiology 
Cancer is a leading cause of death in both developed and developing 
countries. Recently, cancer diseases have become a global health problem. The 
burden of cancer incidence is expected to increase worldwide from 14.1 million 
cases in 2012 to 21.6 million by 2030. In 2012, 8 million cancer related deaths were 
recorded worldwide[4].One of the main reasons for the rising burden of cancer is the 
aging of the population. Furthermore, tobacco and alcohol consumption, obesity 






1.1.3 Cancer characteristics  
Cancer is known as a class of disorders or diseases characterized by 
uncontrolled cell growth and/or defects in vital and critical control mechanisms such 
as the ability to undergo cell death or growth arrest. Additionally, cancer cells are 
characterized by their capability to spread from the primary site, or site of origin, to 
adjacent tissue through invasion, or by embedding into distant sites by metastasis. 
Moreover, cancer cells acquire autonomous growth signals, escape from growth 
inhibitory signals, enable replicative immortality, induce angiogenesis (formation of 
new blood vessels)[7], [8], genome instability and tumor-promoting inflammation 
which are crucial characteristics of cancer. Additionally, they highlighted two other 
merging hallmarks that required further study which are avoiding immune 
destruction and reprogramming energy metabolism[9]. 
1.1.4 Classification of cancer 
Cancers are very diverse, requiring different treatments and diagnoses. More 
than one hundred different types of cancers have been identified. Cancers can be 
classified according to the type of tissue in which they originate. There are five main 
groups, which are carcinoma, sarcoma, myeloma, leukemia and lymphoma. 
Carcinoma start in epithelial tissues, while sarcoma is found in mesoderm derived 
cells (such as bone and muscle) and myeloma originate in the plasma cells of bone 
marrow. Moreover, leukemia is a cancer that is found in the bone marrow and 






1.2 Breast cancer 
 It is noteworthy to mention that breast cancer is one of the major causes of 
death among women throughout the world. Breast cancer is a malignant tumor that 
originates from breast cells. A malignant tumor is made up of a group of cancer cells 
that can invade nearby tissues or metastasize to distant areas of the body. Breast 
cancer occur mostly in women, although men can have it, too[11].  
 Understanding the normal breast structure is necessary in order to understand 
the breast cancer disease. Breast tissues are made up mainly of lobules (glands that 
produce milk), ducts (tubes that transport the milk from the lobules to the nipple and 
it has contracting function) and stroma (connective and fatty tissues surrounding the 
lobules and ducts, blood vessels, and lymphatic vessels)[10], [12], [13]. Cancers 
initiating from ducts are known as ductal carcinomas; while those starting from 
lobules are known as lobular carcinomas[14], [15]. There are a number of factors 
correlated with an increased risk of breast cancer such as age, family history, 
exposure to radiation41 and lifestyle[16]. 
1.2.1 Descriptive epidemiology 
Breast cancer is a serious disease and by far the most frequently diagnosed 
cancer in women on a global scale. In 2012, there were 1.7 million cases and 0.5 
million breast cancer deaths. The incidence of breast cancer accounted for 25.2% of 
all cancer cases and 15% of all cancer deaths in women in 2012. Moreover, breast 
cancer incidence rates in developing countries was 2-fold higher than developed 






countries than in developed countries[5]. It is predicted that by 2030, the number of 
new cases of cancer in the world will increase to 22.2 million[17], [18].  
 In the United Arab Emirates (UAE), cancer is considered to be the third 
leading cause of death after heart diseases and accidents, where cancers cause 15% 
of total deaths. In 2012, 20% of diagnosed cancer cases was breast cancer. Moreover, 
breast cancer is considered to be the leading cause of death among other cancers like 
lung and colon cancers, where it represents 13.3% of all other cancers[19].   
1.2.2 Molecular classification of breast cancers 
Breast cancer is considered to be a highly heterogeneous group of cancers 
that arrive from different cell origins and each has its own clinical implications. 
Breast cancer is classified according to the histopathology, tumor grade, tumor stage, 
and protein profile and gene expression[20].  
 The molecular classification of breast cancer is based on examining the 
alterations of gene expression that drive cancer. This is important as it has prognostic 
significances beyond the traditional prognostic indexes and can aid in the 
determination of the most suitable treatment for the individual. Accordingly, at the 
molecular level, breast cancer can be categorized into five subtypes which are 
luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) 
overexpression, basal-like tumors and normal like tumors[21]–[23]. Normal-like 
tumors are poorly classified and they need more studies and their clinical 






1.2.2.1 Luminal tumors 
 Most breast cancers are luminal-like tumors, representing 64.3% of other 
breast cancer subtypes. They are highly identified among hormone receptor-positive 
cancers like estrogen (ER) and progesterone (PR) receptors[25]. There are two 
subtypes of luminal tumors, i.e., luminal A and luminal B[22]. Luminal A breast 
cancer has been defined as ER+/HER2- and has low Ki67 (proliferation marker)[26], 
while luminal B as ER+/HER2- and has high Ki67[27]. Luminal B tumors are more 
aggressive in comparison with luminal A and have higher histological grade and 
poorer diagnosis. The treatment of this subtype of breast tumor is mainly based on 
endocrine therapy[28]. 
1.2.2.2 HER2 over-expression tumors   
HER2 is a cell membrane receptor tyrosine kinase and it is usually involved 
in the signal transduction pathways leading to cell differentiation and growth[29]. 
Approximately 15% to 20% of all breast cancers correspond to HER2 over-
expression[20]. HER2 is distinguished for its role in the pathogenesis of breast 
cancer and as a target for therapy. HER2 over-expression tumors are highly 
proliferative and aggressive. They have a high histological grade, poor prognosis, 
and are highly sensitive to chemotherapy[30]. Recently, combination of anti-HER2 
therapies showed promising results in response rate and tolerance[31], [32].  
1.2.2.3 Basal-like tumors  
Basal-like breast cancers represents around 10% to 20% of breast carcinomas. 
The term basal-like was coined because this kind of tumors expresses genes that are 
usually found in normal breast myoepithelial cells[33]. According to 






and one of them is the triple negative breast cancer (TNBC) which is negative to ER, 
PR and HER2 receptors[34], [35]. Basal-like breast cancers have different clinical 
presentations, diverse response to chemotherapy, distinctive histological features and 
various outcomes[34], [36].  
1.2.2.3.1 Triple negative tumors  
TNBCs represent 60% to 90% of all basal-like cases and is known to lack the 
expression of ER, PR and HER2[22]. Triple negative is considered to be highly 
aggressive and have high proliferative index compared to other breast cancers[37]. 
Moreover, it is characterized by distinctive molecular profile and  patterns of 
metastasis which usually include brain, lung and bone metastasis[38]. Additionally, 
they have poor prognosis and relapse very quickly compared to other breast cancer 
subtypes[39]. Also, some of the TNBCs are  known to have BRCA1 mutations. 
BRCA1 is essential for DNA repair mechanisms and its inactivation accumulates 
DNA errors and cause genetic instability which could lead to tumor growth[40].  
1.3 Targeted pathways and cellular process in breast cancer 
 At early stages of tumor progression, cancer cells multiply near the site of 
origin where their ancestors first started their uncontrolled proliferation. This results 
in a primary tumor where the cancer cells will proliferate and expand within the 
organ of origin. These primary tumors correspond to about 10% of cancer deaths. 
However, the remaining 90% of deaths were found to have metastasized tumors[41], 
[42]. Metastasis action is followed by the formation of new blood vessels in a 






mechanisms of metastasis and angiogenesis is important to develop new treatments 
and prevention strategies against breast cancer.  
1.3.1 Metastasis  
 Metastasis is defined as a cascade of events which are connected through a 
series of adhesive interaction and invasive processes, along with responses to 
chemotactic stimuli[43], [44]. Metastasis has been characterized as a late stage in 
cancer progression. The formation of metastasis cascade is extremely complex where 
it is composed of several events which correspond to several biological functions. 
The steps involved in metastatic process are: (1) invasion, (2) intravasation, (3) 
transport, (4) extravasation and (5) metastatic colonization[8], [45], [46] (Fig. 1).  
 
Figure 1: Schematic diagram showing the different stages of cancer metastasis. 






 Cancer cells can’t be viewed as an isolated mass of tumor, but instead as 
tissue that receives and recruits signals from surrounding cells, which is termed 
tumor-associated stroma or tumor microenvironment. Tumor microenvironment 
affects the interactions of tumor cells and its ability to metastasize. Breast tumor 
microenvironment is composed of extracellular matrix and different cell types, such 
as fibroblasts, immune cells, endothelial cells and adipocytes[48]. All of these 
components play a role in the carcinogenesis of breast cells and their ability to 
metastasize. 
1.3.1.1 Invasion 
 Invasive and migratory abilities of cancer cells are considered as key features 
of metastatic cascade. In order for cells of primary tumor to invade surrounding 
tissue, they must escape from the normal molecular restrictions that link nearby cells 
to each other. Thus, these tumors cells need to remodel their cell-matrix and cell-cell 
adhesion interactions to gain invasive capabilities[8].  
 Cell adhesion molecules (CAMs) are families of proteins that mediate 
heterotypic (distinct cell types) and homotypic (same cell types) recognition[8]. 
Cadherin is one of the CAMs and it is a transmembranal glycoprotein that interact 
with actin component of the cytoskeleton through catenins[49]. Catenins are 
involved in the maintenance of tight intracellular adhesion interactions. Cadherin-
catenin complexes are also involved in the intracellular signal transduction 
cascades[50]. For instance, cadherin is known to sequester catenin, preventing 
catenin from the association with other downstream signaling, thus possibly 






and its abrogation has been shown to be associated with breast carcinoma and 
showed fibroblast-like and invasive phenotypes[52]–[55]. Moreover, breast cancer 
was shown to display either down-regulation or complete loss of α-, β- and γ-
catenins[50], [56]. However, Hazan et al. (2000) found that transfection of α-catenin 
gene into metastatic epithelial cells resulted in the restoration of intracellular 
adhesion[57]. Moreover, another study showed that the transfection with E-cadherin 
cDNA resulted in the re-establishment of epitheloid phenotype and abrogate their 
invasiveness.  
 Tumor cells must also break free from the interaction with the normal 
extracellular matrix (ECM) components. The interaction between epithelial cell and 
ECM involves integrin receptors. Integrin receptors bind to basement membrane 
(BM) and ECM through the recognition and interaction with various components of 
ECM, such as collagen, fibronectin or laminin, depending on the subunits that form 
the integrin[8], [58]. However, altered expression of integrin is found to be involved 
in breast carcinomas and to facilitate its invasion. Throughout de-adhesion to 
surrounding ECM, consequently tumor cells will be allowed to escape the primary 
tumor.   
 Invasion of cancer cells into adjacent tissues require the action of several 
hydrolytic enzymes or proteases, which are released either by cells around the tumor 
or by the tumor cells themselves[59]. Matrix metalloproteinases (MMPs) and serine 
proteases are two families of proteolytic enzymes implicated in metastasis. The 
MMPs family include several proteases, such as gelatinases, collagenases, 
membrane-type MMPs and other proteases[60]. MMPs production is induced via 






MMPs act on degrading the structural components of ECM and BM and cleave other 
proteins found outside the cells, such as vascular endothelial growth factor (VEGF) 
and fibroblast growth factor (FGF)[61]. Consequently, these proteins (VEGF and 
FGF) play a crucial role in metastasis and stimulate angiogenesis. Up-regulation of 
MMPs were found to be associated with breast, lung and colon tumors.  
 One characteristic of invasive tumor is coordinated by a process termed 
epithelial-mesenchymal transition (EMT) which comprises the conversion of a sheet 
of closely connected epithelial cells into highly mobile mesenchymal cells. This 
process is found commonly at early stages of embryogenesis. Its characterized by 
low expression of epithelial markers (e.g., E-cadherin) and high expression of 
mesenchymal proteins (e.g., N-cadherin) and MMPs. These characteristics were 
observed in metastasized tumors[8], [62]. Currently, several therapeutic agents are 
under study for their capability to decrease cancer invasiveness based on invasion’s 
regulators and their inhibitors[63]. 
1.3.1.2 Intravasation 
 Intravasation involves the entry of invasive carcinoma cells into lymphatic or 
blood vessels and transport them to distant tissues[64]. This process involves several 
steps: (1) cancer cells must adhere to vessel wall, (2) basement membrane 
destruction via MMPs, and (3) transendothelial migration where carcinomas cell pass 







 Transport and circulation of carcinoma cells through the bloodstream and 
lymphatic vessels is in one direction[8]. Once tumor cells enter the bloodstream, they 
are exposed to shear forces and interactions that might lead to their destruction. 
Though, cancer cells are capable of resisting such destruction by attaching to the 
endothelia cells of blood vessels and thereby protecting themselves from the 
immunesystem[66].  
1.3.1.4 Extravasation 
 Extravasation is the escape of tumor cells from lymphatic or blood vessels to 
initiate secondary metastatic out-growth, and it can be taken as the reverse of 
invasion[59], [67]. This process involves the adherence of tumor cells to endothelial 
part of the blood vessel, penetration of endothelial wall, passage through the basal 
membrane, and migration into surrounding stroma[8], [10]. 
1.3.1.5 Metastatic colonization  
 Metastatic colonization is the formation of a progressively growing tumor at 
the secondary tissue. The microenvironment of the new metastatic site differs 
completely from the the site of primary tumor. Cancer metastasis is an organ-
selective event, where carcinomas cells will spread to specific and suitable 
environment in which they grow and develop[68].  
1.3.2 Angiogenesis 
 Successful tumor metastasis cannot be completed without angiogenesis. 






essential role in the formation of new vascular network to provide oxygen and 
nutrients and to remove waste products from cancer cells[69]. Recently, the 
involvement of angiogenesis in tumor progression has been extensively studied.  
1.3.2.1 The process of angiogenesis 
 The regulation of angiogenesis depends on a net balance between anti-
angiogenic factors and pro-angiogenic factors. Pro-angiogenic factors involve 
VEGF, tumor necrosis factor (TNF-α) and other factors that are secreted from tumor 
cells or mobilized from the ECM. The first event in angiogenesis is the ‘angiogenic 
switch’ which is the switch of non-angiogenic tumor to be angiogenic tumor[8].The 
angiogenic switch in tumors involves two main events: (1) up-regulation of pro-
angiogenic factors and/or down-regulation of anti-angiogenic factors; (2) hypoxia 
that activates hypoxia inducible factor-1 (HIF-1), resulting in VEGF production[70]. 
 The process of angiogenesis involves (1) the production of cytokines (by 
carcinoma and surrounding stromal cells) and proteases (by endothelial cells) to 
degrade vascular BM, (2) the migration and proliferation of endothelial cells through 
the breached BM towards tumor cells and formation of endothelial tube (3) 
recruitment and attachment of mesenchymal cells to the endothelial cell tube and  
blood vessels maturation with the formation of vascular basement membrane[64], 
[71]. Several ECM proteins and angiogenic factors are involved in angiogenesis. 
 Upon stimulation of angiogenic factors, proteases such as MMPs get 
activated and start degrading vascular BMs leading to the migration of activated 
endothelial cells into interstitium. Proteases also fragment some ECM proteins such 






Additionally, some of the matrix components, such as fibronectin, fibrin, and others 
were found to guide endothelial cells to their targets and provides a supportive 
scaffold, and subsequently facilitating the formation of neovessels[73].  
1.3.2.2 Factors involved in regulating angiogenesis 
1.3.2.2.1 Angiogenic inducers  
	 Several growth factors and endothelial-specific factors (i.e., VEGF) are 
involved in the induction of angiogenesis. The role of VEGF in angiogenesis 
regulation has been intensely investigated. VEGF is one of the first player in the 
initiation process of angiogenesis. VEGF-signaling is vitally involved in 
physiological and pathological angiogenesis specifically in tumor growth. The VEGF 
gene family comprises of VEGF-A, VEGF-B, VEGF-C, and placental growth factor 
(PlGF)[74]. VEGF-A is a key regulator of blood vessel growth, and VEGF-C and 
VEGF-D are required in lymphatic angiogenesis regulation[8].  
 VEGF induces the proliferation and growth of endothelial cells in vitro , and 
provokes angiogenic response in vivo[74], [75]. Additionally, it induces the survival 
of endothelial cells through activating phosphatidylinositol (PI)-3 kinase-Akt 
pathway and producing anti-apoptotic proteins[76], [77]. Moreover, it promotes 
vascular permeability, causing inflammation and other pathological conditions[78], 
[79]. Also, over expression of VEGF has been studied in various human 
malignancies including breast, colon, and lung cancers. An in situ hybridization 
study of human breast carcinomas samples showed high VEGF expression, 
compared to normal breast cells[80]. Subsequently, VEGF might be a good target for 






1.4 Breast cancer treatments 
 Today’s therapies for breast cancer include several approaches consisting 
mainly of surgery, radiation therapy, chemotherapy, hormonal therapy and combined 
therapy. These approaches can all be used in both the curative and the maintenance 
of curation from breast cancer. 
1.4.1 Conventional treatments for breast cancer  
 Once breast cancer gets diagnosed, usually the treatment is started with either 
surgical removal of discrete tumor from breast (lumpectomy) or the entire diseased 
breast (mastectomy) following adjuvant systemic therapy to decrease the risk of 
relapse. Mastectomy is found to be effective therapeutic approach for breast cancers 
with BRCA mutations[81]. Also, it is commonly used for invasive breast cancers at 
early stages[82]. Lumpectomy is used alone or in combination with radiotherapy, and 
it is reported to be more suitable therapy for invasive breast cancer[83]. 
 Radiotherapy is the exposure to a specific ionizing radiation from an external 
source which will ultimately damage the cells through direct ionization of DNA, 
mediated by (reactive oxygen species) ROS generation via radiation-induced water 
hydrolysis and production other toxic radicals. Moreover, Radiotherapy disturbs 
cellular homeostasis which will trigger the apoptosis pathway. Radiotherapy has an 
important role in the reduction of cancer recurrence and it is applied usually after 
surgery[84].  
 Usually chemotherapy is applied immediately after surgery or before 






cancer that is greater than 1 centimeter. Neo-adjuvant chemotherapy is used to 
reduce the size of a tumor and to prevent the development of micro-metastasis before 
the surgery.  Adjuvant chemotherapy is used to reduce the risk of relapse [86]. There 
are different chemotherapy regimens that are used, each based on specific 
characteristic of the tumor type and status. Generally, the main effect of 
chemotherapy is believed to kill cells by inducing apoptosis in the malignant cells by 
targeting specific cellular mechanisms[87], [88].  
 Breast cancer develops in epithelial tissues of the breast, which are known to 
proliferate under hormonal control. Therefore, breast cancer is often treated with 
endocrine modulators when tumor cells retain their hormonal receptors. For instance, 
tamoxifen, an ER regulator which binds to ER and blocks estrogen from binding to 
it, is usually given to premenopausal women. However, endocrine therapy fails to 
cure TNBCs as they lack hormonal receptors[89].  
1.4.2 Targeted treatments for triple negative breast cancer  
	 TNBCs do not respond to hormonal therapy and they are highly resistance, 
aggressive, metastasize and invasive. At present, many researches are going on to 
further characterize the TNBCs and find target therapies for them. Some clinical 
studies suggested new agents that are effective on the triple negative tumors. 
1.4.2.1 Metastasis inhibitors  
	 While metastasis is the main cause of death in breast cancer patients, anti-
metastatic therapeutic agents are rarely developed. Interestingly, Esak Lee and his 






the growth and metastasis of breast cancer. SP2012 is found to inhibit breast cancer 
growth, metastasis, blocks angiogenesis and lymphangiogenesis. This SP2012 
peptide inhibits lymphatic and blood endothelial cell viability, migration, adhesion, 
and tube formation by targeting MET (mesenchymal-epithelial transition) 
signals[90].  
1.4.2.2 Angiogenesis inhibitors 
	 TNBCs are known to be highly aggressive with enhanced angiogenesis and 
have been found to have high expression of VEGF. A discussed earlier, VEGF is a 
key mediator of angiogenesis, it stimulates endothelial cell proliferation and 
regulates vascular permeability in breast cancer[91]. Therefore, targeted therapy 
against angiogenesis can be preventive for breast cancers.  
 One agent involves targeting angiogenic factors such as VEGF is 
bevacizumab. Bevacizumab is a humanized recombinant monoclonal antibody which 
recognize all  known isoforms of VEGF[92]. A study showed that bevacizumab 
alone has no effect on breast cancer in terms of tumor growth delay. However, a 
combination of bevacizumab with chemotherapy (i.e., docetaxel) showed 47% 
reduction in tumor progression[93]. 
1.4.3 Plant-derived anti-cancer agents  
	 Natural plants have been used as medicine to prevent and to cure several 
diseases for thousands of years. Plants have been found to be an excellent source of 
bioactive compounds which have beneficial health effects, and very often, these 






been found to have anti-cancer activities, therefore, plants became one of the main 
interests for researchers. 
1.4.3.1 Phytochemicals 
 Phytochemicals are natural compounds that are derived from plants. 
Thousands of phytochemicals have proved to possess chemo-preventing activities 
against cancers without having severe side-effects compared to conventional 
treatments[94]. Many cancer therapy researches have aimed to identify and develop 
new chemotherapeutic agents that are derived from plants. Different phytochemicals 
found in diet were tested and were found to have toxic effects on breast cancer cells 
in vitro and prevent breast cancer progression in vivo[95]. Moreover, phytochemicals 
have been shown to target breast cancer through inhibiting cellular proliferation, 
suppressing inflammatory response, arresting cell cycle, causing apoptosis and 
modulating gene expression (such as up-regulation of tumor suppressing genes and 
suppressing angiogenic and invasion genes)[96]. 
 Examples of plant-derived agents in preclinical development are paclitaxel 
and docetaxel taxanes. These are compounds obtained from yew tree and they 
showed anti-tumor activity against metastatic breast cancer and ovarian cancer. They 
also induced mitotic arrest and apoptosis[97], [98]. Another example is DNA 
topoisomerase I inhibitor β-lapachone obtained from the Lapacho tree. It induces cell 
cycle arrest at G1 or S phase and causes apoptotic or necrotic cell death in different 
type of human carcinoma cells, including breast, ovaries, colon, lungs and 
prostate[99]–[101]. Additionally, apigenin is a flavone compound extracted from 






against breast cancer and colon cancer cell lines[102]. Apigenin also has a  
chemoprevention activities against cancer cells and induces a process of autophagic 
cell death[103]. Another plant-derived agent in clinical was derived from a spice 
Bleekeria vitensis. Elliptinium was found to have anti-breast cancer activitiy and is 
marketed in France nowadays[104].  
 During the past decades, there has been substantial progress in identifying 
how certain phytochemicals are able to interfere with specific events in the process 
of carcinogenesis. Epigallocatechin gallate (EGCG) is a chemopreventive and anti-
oxidant polyphenol that is found in green tea. It has been shown that EGCG  
suppressed VEGF production via inhibiting the activation of both STAT3 and NF-κB 
in human breast cancer cell lines[105], [106]. NF-κB has been reveled to be anti-
apoptotic and it stimulates tumor proliferation, while STAT3 is found to be 
associated with tumor metastasis and angiogenesis[107]. Further investigation, are 
needed to understand the anti-carcinogenic actions of phytochemicals. 
1.4.3.1.1 Carnosol 
 Since prehistoric times, mediterranean herbs such as sage and rosemary have 
been used for their medicinal properties and culinary purposes. Sage and rosemary 
have been known to contain various polyphenolic compounds such as carnosol, 
rosmanol, carnosic acid, rosmarinic acid as well as others[108]. Carnosol was first 
isolated from sage in 1942 and its chemical structure identified by Brieskorn et al. in 
1964[109]. Carnosol is a phenolic diterpene and is synthesized from carnosic 
acid[110], [111]. Carnosol was reported to have potent anti-oxidant, anti-






 The accumulation of ROS and the reduction of anti-oxidants have been 
known to promote various biological responses including inflammatory conditions, 
neurodegenerative disease, cardiovascular disease, and carcinogenesis of several 
tissues[113]. Rosemary extracts were revealed to have radical scavenging activity 
which was mainly attributed to carnosol and carnosic acid[114]. Moreover, 
deregulated inflammatory signaling lead to excess nitric oxide (NO) production that 
occur during inflammation and the multi-step process of carcinogenesis. This 
encouraged the search for agents that decrease inflammatory signaling cascades. 
Carnosol was reported to reduce nitric oxide production through the inhibition of 
NF-kB, p38 and mitogen activated protein kinase (MAPK) in mouse macrophages 
which provide possible mechanisms for anti-inflammatory action[115].  
 In addition, carnosol has been shown to elicit chemopreventive effects by 
blocking the activation of carcinogens, inhibiting cell proliferation, inducing 
apoptosis selectively in cancer cells, and blocking tumor angiogenesis and 
invasion[116]. Carnosol repressed proliferation and stimulated apoptosis in several 
human cancer cells. This compound was found to induce cell cycle arrest at G2/M 
phase and to decreased mitotic exit of human colon cancer (Caco-2) cells through up-
regulation of cyclin B expression[117]. Similarly, carnosol induced G2/M phase cell 
cycle arrest in human prostate cancer (PC3) cells through down-regulation of several 
cyclins (A, D1, and D2), and cyclin-dependent kinases (Cdk), and up-regulation of 
Cdk inhibitors (i.e., p21 and p27). Furthermore, carnosol caused apoptosis cell death 
in PC3 cells via activation of caspase-8 and -9, stimulation of Bax and inhibition of 






carnosol in human leukemia (HL-60) cells were associated with G1 arrest, caspase-3 
activation and induction of apoptosis[119].  
 Moreover, carnosol exhibits anti-angiogenic and anti-metastatic properties. 
This phenolic compound was found to prevent the migration of human umbilical vein 
endothelial cells (HUVEC) and human bronchial aortic endothelial cells (BAEC) and 
decreased activity of MMP-2[119]. Also, carnosol repressed  the migration of 
metastatic mouse melanoma (B16/F10) cells in vitro by inhibiting the expression of 
MMP-9[120], [121]. In vivo studies, were survival of rats with acute myeloid 
leukemia was improved by administration of carnosol alone or in combination with 
vitamin D, which revealed a strong anti-proliferative effect[122], [123]. Additionally, 
it was able to decrease tumor multiplicity in a mouse model with colon cancer[124]. 
1.4.3.1.1.1 Carnosol and breast cancer 
 Carnosol was investigated for its anti-breast cancer properties. This 
compound has been shown to have cytotoxic activity against MCF-7 human breast 
cancer cells[125]. Likewise, carnosol was observed to decrease the cellular viability 
of T47D[126], AU565[127], and MDA-MB-231 human breast cancer cells[128]. 
Additionally, the anti-growth activity of carnosol as a single agent or in combination 
with other chemotherapeutic drugs or phytochemicals against breast cancer cell line 
was evaluated. They found that carnosol reduced cellular viability in human breast 
cancer, and suppressed the adhesion of cancer cells to fibronectin. The combination 
therapy with other phytochemicals such as curcumin increased the anti-proliferative 






231 cells. These results provide additional evidence about the anti-breast cancer role 
of carnosol and its potential activity in blocking the growth of tumor cells[129].  
 Recently, our lab investigated the in vitro and in vivo anti-cancer effects of 
carnosol in TNBC and the data were consistent with a model shown in Figure 2[128]. 
They found that carnosol significantly inhibited cellular viability and colony growth 
and induced G2 arrest in the MDA-MB-231. Cell cycle blockade was associated with 
up-regulation of p21/WAF1 expression and down-regulation of p27. Furthermore, 
carnosol was found to induce beclin1-independent autophagy and apoptosis in MDA-
MB-231 cells. The coexistence of both events, apoptosis and autophagy, was 
confirmed by electron microscopy. Autophagy induction was found to be an early 
event, detected within 3 hours post-treatment, which consequently led to apoptosis. 
Carnosol treatment also caused an increase in the levels of phosphorylated 
extracellular signal-regulated kinase 1 and 2 (pERK1/2) in a dose-dependent manner. 
Additionally, they showed that carnosol induced DNA damage, reduced the 
mitochondrial potential and prompted the activation of the intrinsic and extrinsic 
apoptotic pathways. Moreover, they found that carnosol induced a dose-dependent 
production of ROS, and inhibition of ROS by tiron (a ROS scavenger), prevented the 
induction of autophagy and apoptosis and attenuated DNA damage. These findings 
provide a strong evidence that carnosol may be an alternative therapeutic agent 
against the aggressive form of breast cancer and thus deserves more 
exploration[130]. Here, therefore, we decided to expand our study by investigating 









Figure 2: Hypothetical model demonstrating the differential effect of carnosol in 






Chapter 2: Materials and Methods 
	
2.1 Cells culture and reagents  
 Human breast cancer cells MDA-MB-231 were maintained and cultured in 
Dulbecco Minimal Essential Medium (DMEM) (Hyclone, Cramlington, UK). The 
media was complemented with 10% fetal bovine serum (FBS) (Hyclone, 
Cramlington, UK), 100 U/ml penicillin/streptomycin (Hyclone, Cramlington, UK). 
Carnosol was obtained from Sigma Aldrich. TNF-α antibody was obtained from 
Abcam. Antibodies to pSTAT3, β-actin, goat anti-mouse IgG-HRP (sc-2005) and 
goat anti-rabbit IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnology, 
Inc. LY294002 was purchased from Sigma-Aldrich. 
2.2 Wound healing migration assay  
 In brief, MDA-MB-231 cells were grown in 6-well tissue culture dishes until 
they reach confluence stage. A scrape was made over the confluent monolayer with a 
sterile plastic pipette tip of 1 mm diameter. Three wounds were made for each 
sample or well. Afterwards, the plates were washed twice with 1X PBS and 
incubated at 37°C in fresh DMEM supplemented with 10% fetal bovine serum in the 
presence of vehicle (Dimethyl Sulfoxide (DMSO)) or indicated concentrations of 
carnosol. At the bottom side of each dish, three random places were marked where 
the width of the wound was photographed with an inverted microscope at 40X 
magnification (Nikon Ti-U, Nikon). Wound closure was determined by measuring 
the distance (µm) between the edges of the wound at time 0, 6 and 24 hours, using 






by the cells was done as follow: D = (Size of the wound at t = 0 h –size of the wound 
at t = 6 or 24 hours). 
2.3 Matrigel invasion assay 
 Invasiveness of the MDA-MB-231 cells treated with carnosol was tested 
using BD Matrigel Invasion Chamber (8-µm pore size; BD Biosciences, Bedfrord, 
MA, USA) according to manufacturer’s instructions. Briefly, MDA-MB-231cells (1 
x 105 /well) were placed in 0.5 mL of media containing vehicle (0.2% DMSO) or the 
indicated concentration of carnosol were seeded into the upper chambers of the 
system; the bottom wells in the system were filled with DMEM complemented with 
10% fetal bovine serum as a chemo-attractant and then incubated at 37°C for 24 
hours. Non-penetrating cells were removed from the upper surface of the filter with a 
cotton swab. Cells that have migrated though the Matrigel were fixed with 4% 
formaldehyde, stained with DAPI. Fluorescence from DAPI was detected using a 
filter with excitation wavelength of 330–380 nm and barrier filter of 400 nm. DAPI-
stained nuclei were counted in 10 random fields per well using inverted fluorescence 
microscope at 200X magnification (Nikon Ti-U, Nikon). For quantification, the 
assay was done in duplicate and repeated three times. 
2.4 Measurement of matrix metalloproteinases by ELISA  
 Cells were seeded in 6-well tissue culture plates in the presence of vehicle 
(DMSO) or carnosol for 24 hours. The conditioned medium was collected and the 
levels of secreted MMP-9 and MMP-2 were measured using immunoassay kits 






Experiments were repeated three times and the average of three means is represented 
± SEM. 
2.5 Gelatin zymography 
 Gelatin zymography was performed according to Kleiner and 
Stetlerstevenson’s protocol[131]. Briefly, MDA-MB-231 (2.5 x 106) cells were 
incubated in serum-free medium for 24 hours in the presence of vehicle (DMSO) or 
carnosol (25 µM and 50 µM). The conditioned medium was collected, concentrated 
and 30 µg of total protein was determined in 10% polyacrylamide gels containing 
0.1% gelatin. Following electrophoresis, the gels were washed for 1 hour in 2.5% 
(v/v) Triton X-100 to remove SDS and then incubated overnight at 37°C in 50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2 to allow 
proteolysis of the gelatin substrate. Bands corresponding to protein activity were 
visualized thruogh negative staining using 0.5% Coomassie brilliant blue R-250 
(Bio-Rad, Hercules, CA, USA). Illustrative results from two independent 
experiments are shown.  
2.6 RNA extraction and RT-PCR 
 Total RNA from vehicle- or carnosol-treated MDA-MB-231 cells were 
prepared using Trizol reagent as described by the manufacturer (Life Technologies, 
Inc. Grand Island, NY, USA). RNA expression of MMP-9 was determined by RT-
PCR. RT-PCR was performed using the Qiagen OneStep RT-PCR kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instruction. Equal amounts of RNA 
(500 ng) were used as templates in each reaction. The sequences of specific primers 






antisense, 5′- CCCTCAGTGAAGCGGTACAT-3′; GAPDH sense, 5′-
GGCCTCCAAGGAGTAAGACC-3′, and antisense: 5′-
AGGGGTCTACATGGCAACTG-3′. The PCR products were separated by 1.5% 
agarose gel and visualized by ethidium bromide staining. Representative results from 
two independent experiments are shown. 
2.7 Western blotting 
 Cells (1.8 x 106) were seeded in 100 mm culture dishes and cultured for 24 
hours before addition of carnosol at the indicated concentrations. After incubation, 
cells were washed twice with ice-cold PBS, scraped, pelleted and lysed in RIPA 
buffer (Pierce) supplemented with protease inhibitor cocktail (Roche) and 
phosphatase inhibitor (Roche). After incubation for 30 min on ice, cell lysates were 
centrifuged at 14,000 rpm for 20 min at 4°C. Protein concentration of lysates was 
determined by BCA protein assay kit (Thermo Scientific) and the lysates were 
adjusted with lysis buffer. Aliquots of 25 µ g of total cell lysate were resolved onto 
8–15% SDS-PAGE along with PageRuler Plus Prestained Protein Ladder (Thermo 
Scientific). Proteins were transferred to nitrocellulose membranes (Thermo 
Scientific) and blocked for 1 h at room temperature with 5% non-fat dry milk in 
TBST (TBS and 0.05% Tween 20). Incubation with specific primary antibodies was 
performed in blocking buffer overnight at 4°C. Horseradish peroxidase-conjugated 
anti-IgG was used as secondary antibody. Immunoreactive bands were detected by 
ECL chemiluminescent substrate (Thermo Scientific). Where needed, membranes 
were stripped in Restore western blot stripping buffer (Thermo Scientific) according 






2.8 Animal studies 
 All animal experiments were conducted in accordance with the French 
guidelines on the use of animals in scientific investigations with the approval of the 
local Ethical committee, (Institut Albert Bonniot, Grenoble, France: licence protocol 
N°381029 and B3851610001). 
2.9 Chick embryo tumor growth and metastasis assay 
 The chick embryo tumor growth assay (INOVOTION, Grenoble, France) was 
performed as previously described[132], [133]. Briefly, Fertilized White Leghorn 
eggs, obtained from the Société Française de Production Agricole (SFPA, St. Brieuc, 
France), were incubated at 38°C with 60% relative humidity for 10 days. According 
to the French legislation, no ethical approval is needed for scientific 
experimentations using oviparous embryos (decree n° 2013–118, February 1, 2013; 
art. R-214–88). At stage E10, the chorioallantoic membrane (CAM) was dropped by 
drilling a small hole though the eggshell into the air sac and a 1 cm2 window was cut 
in the eggshell above the CAM. Cultured MDA-MB-231-GFP were detached by 
trypsinization, washed with complete medium and suspended in serum free meduim. 
A 50 µL inoculum of 1 x 106 MDA-MB-231-GFP cells was added onto the CAM of 
each egg. Eggs were then randomized in 4 groups of 15 eggs (to get sufficient 
surviving embryos at the end of the experiments). One day later, tumors began to be 
detectable. They were then treated during 8 days, every two days (E11, E13, E15, 
E17), by dropping 100 µL of either carnosol (50 or 150 µ g/mL), colchicine (2 µ M) 
or vehicle (0.02% DMSO in PBS onto the tumor. At E19 the upper portion of the 






from normal CAM tissue and weighted. In parallel, a 1 cm2 portion of the lower 
CAM was collected to evaluate the number of nodules, containing GFP-expressing 
cells. The fluorescent nodules were visualized in situ using whole mounts of tissue 
fixed in 4% formaldehyde in PBS and flattened between a hollow glass slide and a 
thick coverslip. In order to number the nodule, a thorough and complete visual scan 
of the piece of the lower CAM was done using Leica Macrofluo fluorescent 
microscope (Leica Microsystems GmbH) equipped with GFP filter. Chick embryos 
were sacrificed by decapitation. 
2.10 Statistical analysis 
 All statistical analyses were performed using SPSS version 21. Data were 
reported as group mean ± SEM. The data were analyzed via one-way ANOVA. 







Chapter 3: Results 
	
3.1 Carnosol attenuates the migration ability of MDA-MB-231 human breast 
cancer cells 
 Cell migration is a crucial step in many physiological events. However, 
abnormal regulation of cell migration drives progression of various diseases, 
including cancer metastasis and invasion[134]–[136]. Understanding the 
fundamental mechanisms of breast cancer migration is essential for our 
understanding of both the pathology of disease and the effect of drug and its 
mechanism of action on breast cancer cells.  
 Therefore, we investigated the effect of carnosol on the migration ability of 
MDA-MB-231 cells through using wound-healing migration assay. For this purpose, 
we performed the test with two concentrations of carnosol (25 µM and 50 µM) and 
periods of treatment (0, 6 and 24 hrs) that were previously shown to be non-
cytotoxic[128]. As shown in Figure 3A and 3B, carnosol treatment significantly 
inhibited cellular migration in a concentration- and time-dependent manner. Our data 







Figure 3: Carnosol inhibits the migration of MDA-MB-231 human breast cancer 
cells. (A) Confluent culture of MDA-MB-231 cells were wounded by scratching with 
a pipette tip and the cells were incubated in DMEM medium supplemented with 10% 
fetal bovine serum without (control) and with indicated concentrations of carnosol. 
The wound was measured with an inverted microscope 40X magnification and 
photographed. (B) Wound healing assay showing that carnosol inhibited the 
migration of MDA-MB-231 breast cancer cells in time- and concentration-dependent 
manner. Values represent means ± SEM (n=3) distance (µm) that the cells have 






3.2 Carnosol inhibits the invasion potential of MDA-MB-231 cells 
 Invasion of breast cancer cells into surrounding tissue is an initial step in 
tumor metastasis. For that reason, we examined the effect of carnosol on the invasive 
potential of MDA-MB-231cells in Matrigel-coated Boyden chamber in the presence 
of vehicle (DMSO) or carnosol (25 µM). The number of carnosol-treated cells that 
has passed through the Matrigel coated membrane was markedly reduced in 
concentration-dependent manner by 40%, as shown in Figure 4A and 4B. This 


























Figure 4: Carnosol inhibits the invasive activity of MDA-MB-231 cells. (A) MDA-
MB-231 cells were incubated for 24 hrs with or without carnosol (25 µM) and 
LY294002 (20 µM). Cells that invaded into the matrigel were scored as described in 
Materials and Methods. DAPI-stained nuclei of invading cells were photographed at 
100X magnification under an inverted microscope (Nikon Ti-U, Nikon). (B) 
Quantification of invaded MDA-MB-231 into the matrigel. Values represented in 
percent were calculated from three independent experiments and are represented as 
mean ±SEM. Statistical analysis was performed using one-way ANOVA (*p< 0.05, 








3.3 Carnosol suppresses the expression and the activity of MMP-2 and MMP-9 
in MDA-MB-231 cells 
 Invasion of cancer cells into adjacent tissue requires the action of several 
hydrolytic enzymes or proteases (MMPs), which are released either by cells around 
the tumor or by tumor’s cells themselves[59]. MMP-9 and MMP-2, among other 
MMPs, are known to have a critical role in breast cancer cells invasion and 
metastasis[137]. Accordingly, we decided to examine by gelatin zymography assay, 
whether carnosol inhibits breast cancer cells invasion by affecting the activity of 
MMP-9 and MMP-2 enzymes. As it is shown in figure 5A, MMP-9 and MMP-2 
activity was significantly reduced in concentration-dependent manner by carnosol. 
 Toward that, we examined the level of secreted MMP-9 in the conditioned 
medium of carnosol-treated MDA-MB-231cells. The protein level of MMP-9 (Figure 
5B) was found to be significantly reduced in response to carnosol treatment. 
Furthermore, RT-PCR analysis revealed that MMP-9 mRNA level was reduced in 
MDA-MB-231 cells upon treatment with carnosol (Figure 5C). This demonstrates 
that carnosol can inhibit the transcription of MMP-9 gene in these cells. Altogether, 
our results showed that carnosol significantly inhibits both, the expression and the 


























Figure 5: The effect of carnosol on MMP-2 and MMP-9 in MDA-MB-231 cells. (A) 
Activities of MMP-2 and MMP-9 in carnosol-treated MDA-MB-231 cells. Cells 
were treated with 25 and 50 µM carnosol for 24 hrs and then subjected to gelatin 
zymography, as described in Materials and Methods, to analyze the activities of 
MMP-2 and MMP-9. (B) Effects of carnosol on the secretion of MMP-9 in the 
collected conditioned medium of carnosol-treated MDA-MB-231 cells. The levels of 
secreted MMP-9 were determined using immunoassay kits as described in Materials 
and Methods. Experiments were repeated three times and the average of three means 
is represented ± SEM. Student’s t test was performed to determine the significance 
(*p< 0.05 and **p< 0.005). (C) Effects of carnosol on the expression of MMP-9 
mRNA. MDA-MB-231 cells were treated with carnosol (25 and 50 µM) for 24 hrs 
and then subjected to RT-PCR to analyze the mRNA level of MMP-9. GAPDH was 






3.4 Carnosol down-regulates the expression of TNF-α protein in MDA-MB-231 
Cells 
 Several studies reported that tumor necrosis factor-α (TNF-α) has particularly 
an important role in tumor migration, invasion and angiogenesis in various cancer 
including TNBC[138]. Hence, TNF-α should be considered as a target therapeutic 
approach for breast cancer treatment. Because we found that carnosol inhibited cell 
migration and invasion of MDA-MB-231, we sought to examine the effect of 
carnosol on the expression of TNF-α by measuring the protein level of this cytokine. 
Figure 6 shows that carnosol induced a marked reduction of TNF-α protein in MDA-
MB-231 cells. Therefore, our data suggests that down-regulation of TNF-α could 















Figure 6: Effects of carnosol on the expression of TNF-α in MDA-MB-231 cells. 
Western blot quantification of TNF-α protein in carnosol-treated MDA-MB-231 
cells. MDA-MB-231 cells were treated with vehicle (0.2% DMSO) or indicated 
concentrations of carnosol for 24 hrs, and then whole-cell extracts were subjected to 
Western blot analysis for TNF-α and β-actin proteins. Each lane was loaded with 25 







3.5 Carnosol attenuates STAT3 activation in MDA-MB-231 cells  
 Signal transducers and activators of transcription 3 (STAT3) gets activated by 
phosphorylation by various growth factor and is involved in mammary gland 
development[139]. STAT3 is classified as an onco-protein because its constitutive 
activation can mediate tumorgenesis in nude mice and oncogenic transformation in 
cultured cells[140]. Moreover, STAT3 activation can mediate cellular invasion due 
to the regulation of MMP-1 and MMP-2 which mediate cell invasion[141]. It also 
found to promote cellular proliferation, resistance to apoptosis, tumor angiogenesis, 
and migration of cancer cells[142]. 
 Hence, STAT3 is widely recognized as a potential drug target for cancer 
therapy. To investigate whether carnosol affects the activation of STAT3 signaling in 
breast cancer cells, we analyzed the level of pSTAT3 in carnosol-treated MDA-MB-
231 cells. We found that carnosol markedly reduced STAT3 phosphorylation, in 
concentration dependent-manner in MDA-MB-231 cells (Figure 7). This result 
suggests that the carnosol-mediated effect on cell proliferation, migration and 
invasion in breast cancer involves the inhibition of STAT3 signaling in breast cancer 
cells. Taken together, our data clearly indicate that carnosol exerts its effects on 
breast cancer cell proliferation, migration and invasion at least partly through an 
inhibition of one key signaling pathway, namely STAT3, known to regulate several 















Figure 7: Down-regulation of STAT3 in carnosol-treated MDA-MB-231 cells. 
Concentration-dependent decrease of phospho-STAT3 in carnosol-treated MDA-
MB-231 cells. MDA-MB-231 cells were treated with vehicle (0.2% DMSO) or 
indicated concentrations of carnosol for 24 hrs, then whole-cell extracts were 
subjected to Western blot analysis for the phosphorylated form of STAT3 and for β-
actin. Each lane was loaded with 25 µg of whole cell extracts. Loading was 







3.6 Carnosol inhibits tumor growth and metastasis in chick embryo tumor 
growth and metastasis assay 
 To further confirm the in vitro anti-breast cancer activities of carnosol, we 
decided to investigate its effect on tumor growth in vivo by using the chick embryo 
model. MDA-MB-231 cells were grafted on the chorioallantoic membrane (CAM) 
and formed tumors were treated every 48 h with vehicle, colchicine (2 µM) or 
increased concentrations of carnosol (50 and 100 µM). At E 19, tumors were 
recovered from the upper CAM and weighted. As it is shown in Figure 8A and 8B, 
carnosol significantly inhibited tumor growth compared with the vehicle treatment. 
In fact, concentrations of 50 and 100 µM carnosol led to reduced tumor growth by 
43.6% and 33.8% respectively. Similar effect (43.6% inhibition) was obtained with 2 
µM colchicine.  
 We next assessed for the ability of carnosol to inhibit metastasis by counting 
the number of nodules in the lower CAM in vehicle, colchicine and carnosol treated 
tumors. An average of 6.13 nodules were counted in the lower CAM of vehicle-
treated chick embryo, while an average of 0.63 and 0.6 nodules only were counted in 
50 and 100 µM carnosol-treated embryos (Figure 8C). All together, our data clearly 
demonstrates that carnosol could efficiently inhibit breast tumor growth and 









Figure 8: Anti-tumor growth and anti-metastatic activity of carnosol on breast tumor 
in chick embryo chorioallantoic membrane model system. (A) MDA-MB-231 (1 x 
106) cells were grafted on the CAM of 10 day (E10) chick embryo. Tumors were 
treated every 48 hrs with carnosol as described in Materials and Methods. At E19, 
tumors were collected and weighted. (B) Quantification of tumor weight in vehicle 
(DMSO), colchicine and indicated concentrations of carnosol-treated chick embryo. 
(C) Anti-metastatic effect of carnosol. Quantification of nodules observed in the 
lower CAM of chick embryo treated with vehicle (DMSO), colchicine or indicated 
concentrations of carnosol. Columns represents mean; bars represent SEM. 







Chapter 4: Discussion 
	
	 TNBCs represent a challenge for patients and clinicians because of its poor 
prognosis and aggressive behavior, with lack of targeted therapies and high mortality 
in comparison to other subtypes of breast cancer. Therefore, identification of new 
effective therapeutic compounds to treat TNBCs remain an important clinical 
challenge.   
 Cancer progression toward metastasis involves multistep events in which 
malignant cells go into local invasion, intravasation, survival in the circulation, 
extravasation, colonization and angiogenesis[143]. Currently, most agents used for 
cancer treatment aim at blocking specific molecular mechanisms in tumor 
progression, such as, inducing cell death, blocking cell cycle progression or/and 
inhibiting tumor invasion and angiogenesis. Interestingly, numerous phytochemicals 
derived from edible plants have been reported to have anti-cancer activities[105]. 
However, little is known about the mechanism of action of most chemopreventive 
agents. In the present study we investigated the effect of carnosol, a naturally 
occurring compound, against TNBC specifically MDA-MB-231 cell line. Our 
findings demonstrate that carnosol, at non-cytotoxic concentrations, exerts a potent 
anti-metastatic and anti-tumor growth activities against the highly invasive MBA-
MB-231 cell line. Indeed, we report that carnosol inhibited the migration and 
invasion of MDA-MB-231 cells. Moreover, carnosol suppressed the expression and 
activities of MMP-2 and MMP-9. Remarkably, our investigation revealed that TNF-α 
and STAT3 pathways were inhibited in MDA-MB-231 cells in response to carnosol, 






demonstrated that carnosol significantly inhibited tumor growth and metastasis in 
vivo in chick tumor growth assay.   
 Metastases are formed following the completion of a complex succession of 
biological events and the earliest step is migration and invasion through the basement 
membrane and the extracellular matrix. Thus, to study this step of metastasis, we 
assessed the effect of carnosol on cell-ECM and cell-cell interactions and its effect 
on cells migration through in vitro wound or scratch assay. Our results revealed that 
carnosol inhibited cell migration in the MDA-MB-231 cell line. This finding may 
account partially to the anti-metastatic potential of carnosol on TNBCs. For that 
reason, since carnosol exerts its anti-migratory effect on breast cancer cells, we 
speculated that it might be a valuable agent that can interfere with cancer cells 
adhesion to ECM.  
 Tumor invasion involves the entry of cancer cells that have resided within a 
well-confined primary tumor into nearby stroma and thereafter into adjacent normal 
tissue. Invasion is a crucial event in the process of tumor metastasis. It includes the 
secretion of substances to degrade the extracellular matrix and the basement 
membrane and also the regulation of protein expression involved in the control of 
cells motility and migration. MMPs are proteases that are capable of degrading a 
range of extracellular matrix proteins allowing cancer cells to migrate and 
invade[144], [145]. Up to now, there are at least 28 identified MMPs, and 14 of them 
were found to be implicated with breast cancer development and progression[146]. 
Indeed, the up-regulation of MMPs protein expression were found to be associated 
with breast cancer metastatic potential[147]. Moreover, several studies of 






MMPs as prominent molecules involved in modeling tumor microenvironment and 
driving cancer progression and metastasis[148], [149]. Here, we clearly showed that 
carnosol exerts its anti-invasive effect by down-regulating MMP-2 and MM-9 
expression and decreasing their activities. Therefore, through inhibiting these MMPs 
we might have impressive therapeutic effect against metastatic and invasive breast 
cancer. 
 Inflammation within breast tumor microenvironment is known to be 
associated with increased progression and invasiveness and poor prognosis[150], 
[151]. Many inflammatory cytokines are involved in the pathogenesis of breast 
cancer and they have gained increasing attention by researchers. TNF-α is considered 
as key inflammatory cytokine and plays a critical role in the pathogenesis of 
inflammatory responses, autoimmune and malignant diseases[152]. Furthermore, 
TNF-α stimulates the expression of adhesion molecules included in the invasion of 
metastatic tumor cells[153], [154]. Additionally, TNF-α is also a vital molecule in 
stimulation of angiogenesis through  promotion of endothelial cell proliferation and 
improvement of expression of other pro-angiogenic factors[155]. Further, in vitro 
activation of TNF-α induces malignant behavior and invasion in breast cancer 
cells[156]. Hui-Hui Li et al. suggested that up-regulation of TNF-α expression in 
TNBC’s patients is associated with distant tumor metastasis more than other breast 
cancer subtypes[157]. In contrast, the knockdown of TNF-α gene expression was 
found to be associated with the inhibition of cell proliferation and induced apoptosis 
in TNBC[158]. Likewise, inhibition of tumor xenografts in MDA-MB-231 cells by 
docetaxel and ulinastatin was correlated with down-regulation of TNF-α expression 






coriaria suppressed TNF-α production in MDA-MB-231 breast cancer cells[160]. 
Interestingly, here we showed that carnosol inhibited TNF-α expression in MDA-
MB-231 cells. Taken together, our finding strongly suggests that one possible 
mechanism through which carnosol inhibits invasion and tumor growth involves 
inhibition of TNF-α pathway. 
 STAT3 is a cytoplasmic transcription factor that is responsible for signal 
transduction from cell surface receptors to the nucleus. STAT3 activation is tightly 
controlled under normal physiological conditions[142], [161]. However, compelling 
evidence suggest that STAT3 is a master regulator of several key hallmarks of cancer 
cells and is found to be constitutively activated in many cancers including breast 
cancer[7], [9], [162], [163]. This transcription factor plays a pivotal role in tumor 
growth, cellular proliferation[164], resistance to apoptosis regulators[165], invasion, 
migration and angiogenesis[166], [167]. For example, in transgenic mice, mutant 
allele of  constitutively active STAT3 developed significantly more metastatic and 
aggressive tumors than those without[168]. Conversely, Kotha et al. reported that 
resveratrol, a naturally occurring polyphenolic compound, repressed tumor growth 
and induced apoptosis by inhibiting STAT3 signaling in malignant cells like human 
breast cancer (MDA-MB-468 and MDA-MB-231), prostate cancer, human 
pancreatic cancer containing activated STAT3 protein[169]. Moreover, 
Methylsulfonylmethane (MSM), an organic sulfur-containing natural compound, has 
been shown to suppress breast cancer growth by downregulating STAT3 and 
STAT5b pathways[170]. Remarkably, in MDA-MB-231 cells, we showed that 
carnosol inhibited STAT3 production in dose-dependent manner. Thus, STAT3 is an 






 Metastasis is the most lethal aspect of cancer where it involves complex 
events that are linked both temporally and spatially. Since therapeutic failures are 
usually due to an inability to stop the invasion and spread of cancer rather than to 
failure to treat the primary tumor. Experimental methods for studying the metastatic 
properties of tumor cells are essential to design the most favorable therapy and for a 
basic understanding of the mechanism(s) of tumor progression. The chick embryo 
affords a powerful model to assess tumor metastasis in vivo, in which it provides 
accessibility to the chorioallantoic membrane (CAM), a well-vascularized tissue that 
surrounds the chick embryo. This model is inexpensive and convenient and it has 
other advantages: (1) it is immunodeficient, thus tumors will be able to form after 
transplantation onto CAM, (2) invasion and attraction of blood vessels are crucial for 
tumor growth and this can be easily observed in CAM as it surrounds the 
embryo[171], [172]. Therefore, to extend our previous findings we utilized the chick 
embryo CAM metastasis assay to model the metastatic process and the affect of 
carnosol in vivo. Human breast cancer cells (MDA-MB-231) were transplanted into 
CAM’s chick embryo and treated with carnosol. After 19 days, tumors were 
recovered from the upper CAM and weighted and nodules in the lower CAM were 
counted. Interestingly, we found that carnosol inhibits tumor growth and metastasis 
in vivo. All together, our data demonstrate that carnosol could efficiently inhibit 
breast tumor growth and metastasis in vivo. 
 In summary, our data are consistent with a model shown in Figure 9. We 
demonstrated, for the first time, that carnosol exerts a potent anti-invasive, anti-
metastatic and anti-growth effects against the highly proliferative and invasive 






and/or the activity of proteins that regulate cellular migration, invasion and 
angiogenesis such as MMP-9, MMP-2, TNF-α and STAT3. Moreover, this study 
demonstrated that carnosol inhibited tumor growth and metastasis in an in vivo tumor 
growth and metastasis assay. Therefore, our current findings provide the first 
instance of a potential role of carnosol as promising chemopreventive and therapeutic 
agent that inhibits breast cancer growth and metastasis by modulating the expression 
and activities of several target proteins and/or pathways. Currently, there is a 
growing interest in identifying natural derived compounds that affect several targets 
or pathways in breast cancer. Thus carnosol certainly merits a lot of attention and 
further study to identify its downstream mechanisms of action. 
 







Chapter 5: Conclusion 
 
 Chemoprevention by edible phytochemicals is now believed to be an 
inexpensive, acceptable, readily applicable and accessible approach for cancer 
control. Various phytochemicals derived from edible plants have been shown to 
interfere with different stages of tumorgenesis. Many cellular processes and 
mechanisms have been shown to account for the anti-carcinogenic actions of dietary 
components, but attention has recently been focused on intracellular signaling 
cascades as common molecular targets for various chemopreventive phytochemicals. 
 Here, our study has focused on carnosol, a natural compound found in our 
diets, as a potential anti-breast cancer agent. We demonstrated that carnosol 
attenuated breast cancer cell migration, invasion and tumor growth in vivo, at least 
partially, through down-regulating the expression of TNF-α and STAT3 which 
ultimately led to the inhibition of MMP-2 and MMP-9 expression and activity.  
 Nowadays, increasing number of natural products are being evaluated in 
intervention trials for their potential as anti-cancer agents. Even with the major 
advances in our understanding of multi-step tumorgenesis, little is known regarding 
the mechanism of action of most chemopreventive candidates. The anti-cancer effect 
of most dietary phytochemicals are likely to be the sum of several different 
mechanisms. Deregulation or disruption of intracellular signaling pathways 
frequently lead to malignant transformation of cells. Therefore, it is important to 
identify molecules in the signaling cascade that can be affected by phytochemicals to 
permit better assessment of their underlying mechanisms. Therefore, naturally 
occurring phytochemicals are indeed worthy of further assessment and development 
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